Come join me during my round-the-world biotech adventure in October, with events in London and Shanghai — plus
A few years ago I had a chance to do a half-day event in London with a top group of biotech execs, and I’ve been meaning to get back to the Golden Triangle for a return event ever since.
Now, with the Great Around the Biotech World Trip I’m planning for October, that time has arrived.
On October 10, I’m bringing together a great group of leaders in the biotech community for the first annual Endpoints News UK Biopharma Research & Development Summit, hosted at the Silicon Valley Bank auditorium in London.
We’ll be covering key issues like financing trends, the ROI of drug development and new innovation, and how top cancer drug developers in the country are navigating the huge burst of new studies that has swelled the pipeline in recent years.
My panelists include Mene Pangalos, the EVP of Innovative Medicines, at AstraZeneca; Tim Haines
from Abingworth; Kate Bingham at SV Health Investors; John Pottage, CSO at ViiV; Nooman Haque at SVB; David Grainger at Medicxi; Jackie Hunter from BenevolentAI; Mike Rea from IDEA; Malcolm Weir, CEO at Heptares; Niall Martin, CEO from Artios and David Chiswell, the legendary CAT co-founder who now helms Kymab.
Plus a few we have yet to name.
You can read all about the half-day agenda here. If you wanted me to sum up the objective here, I’d say I’m looking for a clear update on the Golden Triangle’s place in this fast-changing biotech world, with investors acting more bullishly than I’ve ever seen. And I’d like to show the biopharma world what it looks like from the perspective of some of the brightest people in the field.
We have a limited number of seats available for an event that will be recorded for a later broadcast. And I’m looking for an audience as great as the panelists who are appearing to discuss current biotech events at the summit. Biopharma execs looking to get into the conversation are heartily welcome. Plus, we have a beer and wine mixer at the end, which should be fun.
It’s a good thing that we are nearly squared away on London, because after a quick trip to Munich for ESMO, I’ll be headed out to Shanghai for a 2-day event we’re managing with our partners in China, PharmCube: US-China Biopharma Innovation & Investment Summit. We’re still bringing together the panels for this, but we have headline events planned with entrepreneur Samantha Du, CEO of Zai Labs, Vivek Ramaswamy from Roivant, John Oyler, the CEO at BeiGene, Jonathan Wang from OrbiMed Asia and Faheem Hasnain, co-founder and executive chairman of Gossamer, who you may recall arranged the $7.2 billion sale of Receptos to Celgene and recently raised $330 million for his new venture.
Plus, we have lots and lots more execs who will be joining us.
We’re going to be talking deals, dollars and renminbi at a crucial intersection for US, Chinese and European players. So why are we asking you to join us? By intermingling key players on both sides of the Pacific — as well as from Europe — we’d like to spark some new talks on collaborations, development deals and financing opportunities. China’s fast-growing industry is changing everything about the global industry, and this is the time to fully explore it and make some connections.
Finally, I’ll be headed down to Australia to keynote the annual AusBiotech gathering, which I’m really looking forward to. And then I plan to sleep on the entire trip back to Vermont.
You may have noticed that our motto here is Endpoints News: The biopharma world is here. We weren’t kidding around.